Pharsight

Drugs facing NCE-1 in 2026

1. Amvuttra patents expiration

AMVUTTRA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10131907 ALNYLAM PHARMS INC Glycoconjugates of RNA interference agents
Aug, 2028

(4 years from now)

US10806791 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(4 years from now)

US9370581 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(4 years from now)

US8828956 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(4 years from now)

US8106022 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(5 years from now)

US10570391 ALNYLAM PHARMS INC RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
Nov, 2032

(8 years from now)

US9399775 ALNYLAM PHARMS INC RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
Nov, 2032

(8 years from now)

US10612024 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(11 years from now)

US11401517 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(11 years from now)

US10683501 ALNYLAM PHARMS INC Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
Jul, 2036

(12 years from now)

US10208307 ALNYLAM PHARMS INC Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
Jul, 2036

(12 years from now)

US11286486 ALNYLAM PHARMS INC Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
Jul, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 13, 2027
Orphan Drug Exclusivity (ODE) Jun 13, 2029

Drugs and Companies using VUTRISIRAN ingredient

NCE-1 date: 2026-06-13

Market Authorisation Date: 13 June, 2022

Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

AMVUTTRA family patents

Family Patents

2. Baxdela patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9539250 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2025

(1 year, 7 months from now)

US8273892 MELINTA Salt and crystalline forms thereof of a drug
Aug, 2026

(2 years from now)

US8871938 MELINTA Process for making quinolone compounds
Sep, 2029

(5 years from now)

USRE46617 MELINTA Process for making quinolone compounds
Dec, 2029

(5 years from now)

US7728143 MELINTA Salt and crystalline forms thereof of a drug
Jun, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8969569 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2025

(1 year, 7 months from now)

US8648093 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2025

(1 year, 7 months from now)

US8252813 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2026

(2 years from now)

US7635773 MELINTA Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(5 years from now)

US9200088 MELINTA Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(5 years from now)

US8410077 MELINTA Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(5 years from now)

US9750822 MELINTA Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(5 years from now)

US9493582 MELINTA Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 19, 2022
Generating Antibiotic Incentives Now (GAIN) Jun 19, 2027

Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient

NCE-1 date: 2026-06-19

Market Authorisation Date: 19 June, 2017

Treatment: Treatment of acute bacterial skin and skin structure infections caused by designated susceptible bacteria in adults

Dosage: TABLET;ORAL

More Information on Dosage

BAXDELA family patents

Family Patents

3. Bludigo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11845867 PROVEPHARM SAS Process for the preparation of indigotindisulfonate sodium (indigo carmine)
Nov, 2036

(12 years from now)

US11499050 PROVEPHARM SAS NA
Dec, 2037

(13 years from now)

US10927258 PROVEPHARM SAS Process for the preparation of Indigotindisulfonate sodium (indigo carmine)
Dec, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 8, 2027

Drugs and Companies using INDIGOTINDISULFONATE SODIUM ingredient

NCE-1 date: 2026-07-08

Market Authorisation Date: 08 July, 2022

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

BLUDIGO family patents

Family Patents

4. Camzyos patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9181200 BRISTOL Pyrimidinedione compounds
Jun, 2034

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9585883 BRISTOL Pyrimidinedione compounds
Jun, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 28, 2029
New Chemical Entity Exclusivity (NCE) Apr 28, 2027
M (M) Jun 15, 2026

Drugs and Companies using MAVACAMTEN ingredient

NCE-1 date: 2026-04-28

Market Authorisation Date: 28 April, 2022

Treatment: Treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms

Dosage: CAPSULE;ORAL

More Information on Dosage

CAMZYOS family patents

Family Patents

5. Cibinqo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9545405 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(10 years from now)

US9035074 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549929 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 14, 2027
New Patient Population (NPP) Feb 9, 2026

Drugs and Companies using ABROCITINIB ingredient

NCE-1 date: 2026-01-14

Market Authorisation Date: 14 January, 2022

Treatment: Treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable

Dosage: TABLET;ORAL

More Information on Dosage

CIBINQO family patents

Family Patents

6. Cresemba patents expiration

CRESEMBA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6812238 ASTELLAS N-substituted carbamoyloxyalkyl-azolium derivatives
Oct, 2025

(1 year, 8 months from now)

US10812238 ASTELLAS Configurable reference signals
Oct, 2025

(1 year, 8 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6812238

(Pediatric)

ASTELLAS N-substituted carbamoyloxyalkyl-azolium derivatives
May, 2026

(2 years from now)

US10603280 ASTELLAS Active ingredient containing stabilised solid medicinal forms and methods for the production thereof
Sep, 2027

(3 years from now)

US10206879 ASTELLAS Active ingredient containing stabilised solid forms and method for the production thereof
Sep, 2027

(3 years from now)

US10206879

(Pediatric)

ASTELLAS Active ingredient containing stabilised solid forms and method for the production thereof
Mar, 2028

(4 years from now)

US10603280

(Pediatric)

ASTELLAS Active ingredient containing stabilised solid medicinal forms and methods for the production thereof
Mar, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 8, 2030
New Chemical Entity Exclusivity (NCE) Mar 6, 2020
New Patient Population (NPP) Dec 8, 2026
ODE* (ODE*) Mar 6, 2022
Pediatric Exclusivity (PED) Jun 8, 2027
Generating Antibiotic Incentives Now (GAIN) Sep 6, 2027

Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient

NCE-1 date: 2026-06-08

Market Authorisation Date: 06 March, 2015

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

CRESEMBA family patents

Family Patents

7. Elucirem patents expiration

ELUCIREM's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8114863 GUERBET Compounds comprising short aminoalcohol chains and metal complexes for medical imaging
Sep, 2028

(4 years from now)

US10973934 GUERBET Gadolinium bearing PCTA-based contrast agents
Aug, 2039

(15 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11590246 GUERBET Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process
Jan, 2040

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 21, 2027

Drugs and Companies using GADOPICLENOL ingredient

NCE-1 date: 2026-09-21

Market Authorisation Date: 21 September, 2022

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

ELUCIREM family patents

Family Patents

8. Krazati patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10689377 MIRATI THERAPS KRas G12C inhibitors
May, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 12, 2027
Orphan Drug Exclusivity (ODE) Dec 12, 2029

Drugs and Companies using ADAGRASIB ingredient

NCE-1 date: 2026-12-12

Market Authorisation Date: 12 December, 2022

Treatment: Treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda approved test, who have received at least one prior system...

Dosage: TABLET;ORAL

More Information on Dosage

KRAZATI family patents

Family Patents

9. Lytgobi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9108973 TAIHO ONCOLOGY 3,5-disubstituted alkynylbenzene compound and salt thereof
Feb, 2033

(9 years from now)

US10434103 TAIHO ONCOLOGY Crystal of 3,5-disubstituted benzene alkynyl compound
Mar, 2036

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11833151 TAIHO ONCOLOGY Pharmaceutical composition including sodium alkyl sulfate
Nov, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 30, 2027
Orphan Drug Exclusivity (ODE) Sep 30, 2029

Drugs and Companies using FUTIBATINIB ingredient

NCE-1 date: 2026-09-30

Market Authorisation Date: 30 September, 2022

Treatment: Method of treating intrahepatic cholangiocarcinoma

Dosage: TABLET;ORAL

More Information on Dosage

LYTGOBI family patents

Family Patents

10. Mounjaro patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9474780 ELI LILLY AND CO GIP and GLP-1 co-agonist compounds
Jan, 2036

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8734394 ELI LILLY AND CO Automatic injection device with delay mechanism including dual functioning biasing member
Feb, 2031

(7 years from now)

US9402957 ELI LILLY AND CO Automatic injection device with delay mechanism including dual functioning biasing member
Jun, 2031

(7 years from now)

US11357820 ELI LILLY AND CO GIP/GLP1 agonist compositions
Jun, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 13, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: 2026-05-13

Market Authorisation Date: 13 May, 2022

Treatment: Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

MOUNJARO family patents

Family Patents

11. Omlonti patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8648097 SANTEN Pyridylaminoacetic acid compound
Oct, 2029

(5 years from now)

US10774072 SANTEN Crystal of N-substituted sulfonamide compound
Jun, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685986 SANTEN Medical composition for treatment or prophylaxis of glaucoma
Oct, 2029

(5 years from now)

US10765750 SANTEN Pharmaceutical composition containing pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

US11197849 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

US10702511 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

US9415038 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

USRE48183 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

US10179127 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

US11666563 SANTEN Pharmaceutical preparation containing pyridyl aminoacetic acid compound
Jul, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 22, 2027

Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient

NCE-1 date: 2026-09-22

Market Authorisation Date: 22 September, 2022

Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage

OMLONTI family patents

Family Patents

12. Omlonti patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11793798 VISIOX PHARMA Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 22, 2027

Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient

NCE-1 date: 2026-09-22

Market Authorisation Date: 22 September, 2022

Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage

OMLONTI family patents

Family Patents

13. Pluvicto patents expiration

PLUVICTO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11318121 AAA USA NOVARTIS PSMA binding ligand-linker conjugates and methods for using
Aug, 2028

(4 years from now)

US10406240 AAA USA NOVARTIS PSMA binding ligand-linker conjugates and methods for using
Aug, 2028

(4 years from now)

US10398791 AAA USA NOVARTIS Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
Oct, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 23, 2027

Drugs and Companies using LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN ingredient

NCE-1 date: 2026-03-23

Market Authorisation Date: 23 March, 2022

Treatment: For treatment of adult patients with prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with androgen receptor (ar) pathwa...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

PLUVICTO family patents

Family Patents

14. Pyrukynd patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE49582 AGIOS PHARMS INC Therapeutic compounds and compositions
Feb, 2031

(7 years from now)

US8785450 AGIOS PHARMS INC Therapeutic compounds and compositions
Feb, 2031

(7 years from now)

US11254652 AGIOS PHARMS INC Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
Nov, 2038

(14 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9980961 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
May, 2032

(8 years from now)

US9682080 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
May, 2032

(8 years from now)

US10632114 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
May, 2032

(8 years from now)

US9193701 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
Oct, 2032

(8 years from now)

US11793806 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
Apr, 2033

(9 years from now)

US11234976 AGIOS PHARMS INC Methods of using pyruvate kinase activators
Oct, 2038

(14 years from now)

US11878049 AGIOS PHARMS INC Mitapivat therapy and modulators of cytochrome P450
Jul, 2041

(17 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 17, 2029
New Chemical Entity Exclusivity (NCE) Feb 17, 2027

Drugs and Companies using MITAPIVAT SULFATE ingredient

NCE-1 date: 2026-02-17

Market Authorisation Date: 17 February, 2022

Treatment: Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency; Method for increasing the lifetime of red blood cells (rbcs) for the t...

Dosage: TABLET;ORAL

More Information on Dosage

PYRUKYND family patents

Family Patents

15. Quviviq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9732075 IDORSIA Benzimidazole-proline derivatives
Jun, 2033

(9 years from now)

US9790208 IDORSIA Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
Dec, 2034

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10023560 IDORSIA Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
Dec, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 7, 2027

Drugs and Companies using DARIDOREXANT HYDROCHLORIDE ingredient

NCE-1 date: 2026-04-07

Market Authorisation Date: 07 April, 2022

Treatment: Treatment of insomnia

Dosage: TABLET;ORAL

More Information on Dosage

QUVIVIQ family patents

Family Patents

16. Relyvrio patents expiration

RELYVRIO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9872865 AMYLYX Compositions for improving cell viability and methods of use thereof
Dec, 2033

(9 years from now)

US11071742 AMYLYX Compositions for improving cell viability and methods of use thereof
Dec, 2033

(9 years from now)

US10251896 AMYLYX Compositions for improving cell viability and methods of use thereof
Dec, 2033

(9 years from now)

US10857162 AMYLYX Compositions for improving cell viability and methods of use thereof
Dec, 2033

(9 years from now)

US11583542 AMYLYX NA
Jul, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 29, 2027
Orphan Drug Exclusivity (ODE) Sep 29, 2029

Drugs and Companies using SODIUM PHENYLBUTYRATE; TAURURSODIOL ingredient

NCE-1 date: 2026-09-29

Market Authorisation Date: 29 September, 2022

Treatment: Treatment of amyotrophic lateral sclerosis (als) in adults

Dosage: FOR SUSPENSION;ORAL

More Information on Dosage

RELYVRIO family patents

Family Patents

17. Rezlidhia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9834539 RIGEL PHARMS INC Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Sep, 2035

(11 years from now)

US10532047 RIGEL PHARMS INC Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
May, 2039

(15 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10550098 RIGEL PHARMS INC Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Sep, 2035

(11 years from now)

US11498913 RIGEL PHARMS INC Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Sep, 2035

(11 years from now)

US10414752 RIGEL PHARMS INC Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Sep, 2035

(11 years from now)

US11376246 RIGEL PHARMS INC Inhibiting mutant IDH-1
May, 2039

(15 years from now)

US10959994 RIGEL PHARMS INC Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
May, 2039

(15 years from now)

US11497743 RIGEL PHARMS INC Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation
May, 2039

(15 years from now)

US11013733 RIGEL PHARMS INC Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
May, 2039

(15 years from now)

US11013734 RIGEL PHARMS INC Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
May, 2039

(15 years from now)

US11738018 RIGEL PHARMS INC Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
Jul, 2039

(15 years from now)

US11723905 RIGEL PHARMS INC Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
Nov, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 1, 2027
Orphan Drug Exclusivity (ODE) Dec 1, 2029

Drugs and Companies using OLUTASIDENIB ingredient

NCE-1 date: 2026-12-01

Market Authorisation Date: 01 December, 2022

Treatment: A method of treating acute myeloid leukemia (aml) in patients with an isocitrate dehydrogenase-1 (idh1) mutation; A method of treating a cancer characterized by an idh1 mutation where the cancer is ac...

Dosage: CAPSULE;ORAL

More Information on Dosage

REZLIDHIA family patents

Family Patents

18. Solosec patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11324721 LUPIN Secnidazole for use in the treatment of trichomoniasis
Sep, 2035

(11 years from now)

US11000507 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(11 years from now)

US10335390 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(11 years from now)

US11602522 LUPIN Secnidazole for use in the treatment of sexually transmitted infection
Sep, 2035

(11 years from now)

US11020377 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(11 years from now)

US11000508 LUPIN Secnidazole for use in the treatment of trichomoniasis
Sep, 2035

(11 years from now)

US10682338 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(11 years from now)

US10849884 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(11 years from now)

US10857133 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(11 years from now)

US11684607 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 15, 2022
New Indication (I) Jun 30, 2024
New Patient Population (NPP) Jan 26, 2025
Generating Antibiotic Incentives Now (GAIN) Sep 15, 2027

Drugs and Companies using SECNIDAZOLE ingredient

NCE-1 date: 2026-09-15

Market Authorisation Date: 15 September, 2017

Treatment: Treatment of bacterial vaginosis in adult women; Treatment of trichomoniasis in adults; Treatment of bacterial vaginosis in female patients 12 years of age and older; Treatment of trichomoniasis in pa...

Dosage: GRANULE;ORAL

More Information on Dosage

SOLOSEC family patents

Family Patents

19. Sotyktu patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE47929 BRISTOL Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
Nov, 2033

(9 years from now)

US10000480 BRISTOL Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
Nov, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11021475 BRISTOL Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
Nov, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 9, 2027

Drugs and Companies using DEUCRAVACITINIB ingredient

NCE-1 date: 2026-09-09

Market Authorisation Date: 09 September, 2022

Treatment: Treatment of moderate-to-severe plaque psoriasis in adults who are canididates for systemic therapy or phototherapy

Dosage: TABLET;ORAL

More Information on Dosage

SOTYKTU family patents

Family Patents

20. Sunlenca patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9951043 GILEAD SCIENCES INC Therapeutic compounds
Feb, 2034

(10 years from now)

US10071985 GILEAD SCIENCES INC Therapeutic compounds
Aug, 2037

(13 years from now)

US11267799 GILEAD SCIENCES INC Solid forms of an HIV capsid inhibitor
Aug, 2038

(14 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10654827 GILEAD SCIENCES INC Therapeutic compounds
Aug, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 22, 2027

Drugs and Companies using LENACAPAVIR SODIUM ingredient

NCE-1 date: 2026-12-22

Market Authorisation Date: 22 December, 2022

Treatment: In combination with other antiretroviral(s), for the treatment of hiv-1 infection in heavily-treatment experienced adults with multidrug resistant hiv-1 infection

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

SUNLENCA family patents

Family Patents

21. Terlivaz patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10335452 MALLINCKRODT IRELAND Method of treating patients with hepatorenal syndrome type 1
Apr, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 14, 2027
Orphan Drug Exclusivity (ODE) Sep 14, 2029

Drugs and Companies using TERLIPRESSIN ACETATE ingredient

NCE-1 date: 2026-09-14

Market Authorisation Date: 14 September, 2022

Treatment: A method to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

TERLIVAZ family patents

Family Patents

22. Vabomere patents expiration

VABOMERE Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8680136 REMPEX Cyclic boronic acid ester derivatives and therapeutic uses thereof
Aug, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10183034 REMPEX Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives
Aug, 2031

(7 years from now)

US9694025 REMPEX Cyclic boronic acid ester derivatives and therapeutic uses thereof
Aug, 2031

(7 years from now)

US10561675 REMPEX Cyclic boronic acid ester derivatives and therapeutic uses thereof
Aug, 2031

(7 years from now)

US11007206 REMPEX Cyclic boronic acid ester derivatives and therapeutic uses thereof
Aug, 2031

(7 years from now)

US10172874 REMPEX Pharmaceutical compositions comprising cyclic boronic acid ester derivatives
Aug, 2031

(7 years from now)

US11376237 REMPEX Methods of treating bacterial infections
Apr, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 29, 2022
Generating Antibiotic Incentives Now (GAIN) Aug 29, 2027

Drugs and Companies using MEROPENEM; VABORBACTAM ingredient

NCE-1 date: 2026-08-29

Market Authorisation Date: 29 August, 2017

Treatment: Treatment of complicated urinary tract infection (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli, klebsiella pneumonia, and enterobacter cloacae sp...

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

VABOMERE family patents

Family Patents

23. Veklury patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8318682 GILEAD SCIENCES INC 1′substituted carba-nucleoside analogs for antiviral treatment
Apr, 2029

(5 years from now)

USRE46762 GILEAD SCIENCES INC 1′-substituted carba-nucleoside analogs for antiviral treatment
Apr, 2029

(5 years from now)

US8008264 GILEAD SCIENCES INC 1′-substituted carba-nucleoside analogs for antiviral treatment
Sep, 2029

(5 years from now)

US10065958 GILEAD SCIENCES INC Methods and compounds for treating Paramyxoviridae virus infections
Sep, 2031

(7 years from now)

US11492353 GILEAD SCIENCES INC Methods and compounds for treating Paramyxoviridae virus infections
Dec, 2031

(7 years from now)

US9949994 GILEAD SCIENCES INC Methods for treating Filoviridae virus infections
Oct, 2035

(11 years from now)

US9724360 GILEAD SCIENCES INC Methods for treating Filoviridae virus infections
Oct, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8318682

(Pediatric)

GILEAD SCIENCES INC 1′substituted carba-nucleoside analogs for antiviral treatment
Oct, 2029

(5 years from now)

USRE46762

(Pediatric)

GILEAD SCIENCES INC 1′-substituted carba-nucleoside analogs for antiviral treatment
Oct, 2029

(5 years from now)

US8008264

(Pediatric)

GILEAD SCIENCES INC 1′-substituted carba-nucleoside analogs for antiviral treatment
Mar, 2030

(6 years from now)

US10065958

(Pediatric)

GILEAD SCIENCES INC Methods and compounds for treating Paramyxoviridae virus infections
Mar, 2032

(8 years from now)

US11492353

(Pediatric)

GILEAD SCIENCES INC Methods and compounds for treating Paramyxoviridae virus infections
Jun, 2032

(8 years from now)

US9949994

(Pediatric)

GILEAD SCIENCES INC Methods for treating Filoviridae virus infections
Apr, 2036

(12 years from now)

US9724360

(Pediatric)

GILEAD SCIENCES INC Methods for treating Filoviridae virus infections
Apr, 2036

(12 years from now)

US10695361 GILEAD SCIENCES INC Methods for treating arenaviridae and coronaviridae virus infections
Sep, 2036

(12 years from now)

US11007208 GILEAD SCIENCES INC Methods for treating arenaviridae and coronaviridae virus infections
Sep, 2036

(12 years from now)

US11382926 GILEAD SCIENCES INC Methods for treating Arenaviridae and Coronaviridae virus infections
Sep, 2036

(12 years from now)

US10695361

(Pediatric)

GILEAD SCIENCES INC Methods for treating arenaviridae and coronaviridae virus infections
Mar, 2037

(13 years from now)

US11382926

(Pediatric)

GILEAD SCIENCES INC Methods for treating Arenaviridae and Coronaviridae virus infections
Mar, 2037

(13 years from now)

US11007208

(Pediatric)

GILEAD SCIENCES INC Methods for treating arenaviridae and coronaviridae virus infections
Mar, 2037

(13 years from now)

US11266681 GILEAD SCIENCES INC Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Jul, 2038

(14 years from now)

US10675296 GILEAD SCIENCES INC Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Jul, 2038

(14 years from now)

US10675296

(Pediatric)

GILEAD SCIENCES INC Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Jan, 2039

(14 years from now)

US11266681

(Pediatric)

GILEAD SCIENCES INC Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Jan, 2039

(14 years from now)

US11491169 GILEAD SCIENCES INC Remdesivir treatment methods
May, 2041

(17 years from now)

US11491169

(Pediatric)

GILEAD SCIENCES INC Remdesivir treatment methods
Nov, 2041

(17 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 22, 2025
New Patient Population (NPP) Apr 25, 2025
New Dosing Schedule (D) Jan 21, 2025
M (M) Jul 13, 2026
Pediatric Exclusivity (PED) Jan 13, 2027

Drugs and Companies using REMDESIVIR ingredient

NCE-1 date: 2026-01-13

Market Authorisation Date: 22 October, 2020

Treatment: Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 12 years of age and 40 kg) requiring hospitalization; Treatment of coronavirus disease 2019 (covid-19) in no...

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

More Information on Dosage

VEKLURY family patents

Family Patents

24. Vonjo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8153632 CTI BIOPHARMA CORP Oxygen linked pyrimidine derivatives
Jan, 2029

(4 years from now)

US8980873 CTI BIOPHARMA CORP 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
Mar, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9573964 CTI BIOPHARMA CORP Oxygen linked pyrimidine derivatives
May, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 28, 2029
New Chemical Entity Exclusivity (NCE) Feb 28, 2027

Drugs and Companies using PACRITINIB CITRATE ingredient

NCE-1 date: 2026-02-28

Market Authorisation Date: 28 February, 2022

Treatment: Use of pacritinib for inhibiting janus associated kinase 2(jak2); Treatment of myelofibrosis with pacritinib

Dosage: CAPSULE;ORAL

More Information on Dosage

VONJO family patents

Family Patents

25. Voquezna patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7977488 PHATHOM 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors
Aug, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186411 PHATHOM Pharmaceutical composition
Aug, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Nov 1, 2026
New Chemical Entity Exclusivity (NCE) May 3, 2027

Drugs and Companies using VONOPRAZAN FUMARATE ingredient

NCE-1 date: 2026-05-03

Market Authorisation Date: 01 November, 2023

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

VOQUEZNA family patents

Family Patents

26. Vtama patents expiration

VTAMA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10647649 DERMAVANT SCI Process for preparing tapinarof
Nov, 2038

(14 years from now)

US11597692 DERMAVANT SCI Process for preparing tapinarof
Nov, 2038

(14 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10195160 DERMAVANT SCI Topical pharmaceutical compositions
May, 2036

(12 years from now)

US11458108 DERMAVANT SCI NA
May, 2036

(12 years from now)

US11612573 DERMAVANT SCI Topical pharmaceutical compositions
May, 2036

(12 years from now)

US11617724 DERMAVANT SCI Topical pharmaceutical compositions
May, 2036

(12 years from now)

US10426743 DERMAVANT SCI Topical pharmaceutical compositions
May, 2036

(12 years from now)

US11622945 DERMAVANT SCI Topical pharmaceutical compositions
May, 2036

(12 years from now)

US11590088 DERMAVANT SCI Use of Tapinarof for the treatment of chronic plaque psoriasis
Nov, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 23, 2027

Drugs and Companies using TAPINAROF ingredient

NCE-1 date: 2026-05-23

Market Authorisation Date: 23 May, 2022

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: CREAM;TOPICAL

More Information on Dosage

VTAMA family patents

Family Patents

27. Xenoview patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10583205 POLAREAN Hyperpolarized noble gas production systems with nanocluster suppression, detection and/or filtering and related methods and devices
Feb, 2035

(11 years from now)

US11052161 POLAREAN Hyperpolarized noble gas production systems with nanocluster suppression, detection and/or filtering and related methods and devices
Dec, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 23, 2027

Drugs and Companies using XENON XE-129 HYPERPOLARIZED ingredient

NCE-1 date: 2026-12-23

Market Authorisation Date: 23 December, 2022

Treatment: NA

Dosage: GAS;INHALATION

More Information on Dosage

XENOVIEW family patents

Family Patents

28. Zepbound patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9474780 ELI LILLY AND CO GIP and GLP-1 co-agonist compounds
Jan, 2036

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8734394 ELI LILLY AND CO Automatic injection device with delay mechanism including dual functioning biasing member
Feb, 2031

(7 years from now)

US9402957 ELI LILLY AND CO Automatic injection device with delay mechanism including dual functioning biasing member
Jun, 2031

(7 years from now)

US11357820 ELI LILLY AND CO GIP/GLP1 agonist compositions
Jun, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Nov 8, 2026
New Chemical Entity Exclusivity (NCE) May 13, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: 2026-05-13

Market Authorisation Date: 08 November, 2023

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

ZEPBOUND family patents

Family Patents

29. Ztalmy patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9029355 MARINUS Solid ganaxolone compositions and methods for the making and use thereof
Nov, 2026

(2 years from now)

US9056116 MARINUS Liquid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(2 years from now)

US8367651 MARINUS Solid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(2 years from now)

US8618087 MARINUS Solid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(2 years from now)

US7858609 MARINUS Solid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(2 years from now)

US8022054 MARINUS Liquid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(2 years from now)

US8318714 MARINUS Liquid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(2 years from now)

US10603308 MARINUS Methods and compositions for treatment of epileptic disorders
Aug, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 1, 2027
Orphan Drug Exclusivity (ODE) Jun 1, 2029

Drugs and Companies using GANAXOLONE ingredient

NCE-1 date: 2026-06-01

Market Authorisation Date: 01 June, 2022

Treatment: Treatment of seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 years of age and older

Dosage: SUSPENSION;ORAL

More Information on Dosage

ZTALMY family patents

Family Patents